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Abstract
Background: Pancreaticoduodenectomies (PD) still have a substantial mortality rate. Recently, differ-
ent scores have been published to predict the mortality risk pre-operatively after PD. This retrospective
study was designed to perform an external assessment of an Early Mortality Risk Score (EMRS).
Methods: From 2000 to 2012, all PD cases performed at our institution were documented. Only
patients treated for pancreatic head adenocarcinomas were included. Survival time and EMRS (based
on age, tumour size, tumour differentiation and comorbidities) were calculated for every patient.
Relative risks (RR) of early death 9 and 12 months after PD were then calculated.
Results: Of 270 PD for various aetiologies, 120 PD for adenocarcinomas were included. The median
follow-up was 37 months, and the overall median survival was 19 months. EMRS of 4 showed a mortality
RR of 5.1 at 9 months (P = 0.048) and of 4.5 at 12 months (P = 0.020).
Conclusions: EMRS of 4 is a predictor of tumour-related mortality at 9 and 12 months after PD for
adenocarcinoma. The EMRS was externally assessed in our patient cohort and can be implemented in
clinical practice. Clinical implications of this score still need to be studied.
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Introduction
Pancreatic cancer is the fourth cause of cancer-related mortal-
ity in the United States and is predicted to become the second
leading cause of cancer death by 2020.1,2
Technically, pancreas surgery has made important progress
during the two recent decades and has become a safe proce-
dure with mortality rates below 5% in experienced centres with
high patient volumes.3–5 Nevertheless, it has to be emphasized
that post-operative complication rates remain high, ranging
from 20% to 60%, and even more important, long-term sur-
vival is still poor with a reported 5-year survival <20% for
operated patients with curative intent.6–9 One-year mortality of
patients undergoing a pancreaticoduodenectomy (PD) for ade-
nocarcinoma can be as high as 30%.10
The development of pancreas cancer takes several years from
first mutations of tumour suppressor genes to clones of
tumour cells with metastatic capacity, and finally macroscopi-
cally established cancer.11–13 Unfortunately, the majority of the
carcinogenesis steps cannot be detected by current diagnostic
tools; subsequently, clinical diagnosis is established late, and
patients often present locally non-resectable or even metastatic
disease.14 Until earlier tumour detection will be feasible, careful
patient selection remains crucial to identify potential candi-
dates who could benefit from pancreas resection. If surgery is
considered too risky for an individual patient, alternative treat-
ment options such as chemotherapy, eventually combined with
local tumour destruction or radiotherapy could fit better.
Patients with good chances for a prolonged long-term survival
should undergo surgery, and surgery-related morbidity is
acceptable, whereas in patients with predicted limited survival,
i.e. <12 months, preservation of a reasonable quality of life is
more important.10,15,16
To this end, different pre- and post-operative scores using
various risk factors have been developed and may be used to
ease decision-making and to tailor treatment plans for individ-
ual patients.7,9,17–22 One of these, the Early Mortality Risk
Score (EMRS) created by Hsu et al. from Johns Hopkins Uni-
versity is a simple four-item score. With a goal of identifying
HPB 2015, 17, 605–610 ª 2015 International Hepato-Pancreato-Biliary Association
DOI:10.1111/hpb.12422 HPB
patients at high risk of early mortality after pancreas surgery,
the EMRS is a predictive risk score of early death (9 and
12 months) after pancreatic head resection for adenocarci-
noma.18 It includes patient age, tumour size, tumour differen-
tiation and comorbidities.18 This score was selected because it
can be obtained pre-operatively and it is easy to use and calcu-
late.
This present study aimed to assess the EMRS with a differ-
ent cohort and in different settings to test its clinical applica-
bility.18
Methods
Early Mortality Risk Score developed by the group
from Johns Hopkins Hospital
Providing pre-operative data, this score enables prediction of
the 9- and 12-month mortality risk for patients undergoing
PD for pancreatic adenocarcinoma.18 The four parameters
(0 or 1 point for each score parameter) that compose this
score are the age (1 point if >75 years), the tumour size
measured on a CT scan (1 point if ≥3 cm), the tumour differ-
entiation (1 point if poor differentiation) and the comorbidi-
ties (1 point if presence of any one of these: hypertension,
diabetes mellitus, cardiac disease, or chronic obstructive
pulmonary disease). A score ≥2 is significantly associated with
the 9- and 12-month mortality risk. In case of absence of pre-
operative histology, Hsu et al. developed the modified EMRS
(mEMRS) allowing to take simply into consideration age,
tumour size and comorbidities without changing the prognostic
validity of the score.
Database and collected information
The Department of Visceral Surgery of the University Hospital
of Lausanne (CHUV), Switzerland, maintains a prospective
database of all pancreas resections since 2000. It encompasses
more than 150 items of pre-, intra- and post-operative data.23
For this current analysis, only patients who underwent PD
with curative intent for adenocarcinoma of the pancreatic head
from 2000 to 2012 were included, whereas other tumour
entities were not considered. Patients who died during the
60 days after the operation or during their hospital stay after
the index operation were excluded as done in the original
EMRS article.
Technical aspects of the operation and discharge
criteria
Most performed PD (n = 105, 87.5%) were classic pancreatic
head resections, and 15 patients had a pylorus-preserving PD
(12.5%). The pancreatic head was resected en-bloc together
with the duodenum, the distal common bile duct, as well as
the distal stomach. Moreover, the resection also included the
first jejunal loop, the gallbladder and the loco-regional lymph
nodes. An omega-type jejunal loop reconstruction was the
standard procedure consisting of a pancreatico-enteric anasto-
mosis, a bilio-enteric anastomosis and lastly a gastro-enteric
anastomosis. In a few cases, a pancreaticogastric anastomosis
was performed by one surgeon who preferred this technique in
case of soft pancreas texture. Two drains were routinely left in
place near the pancreatico-enteric and bilio-enteric anastomo-
ses. They were removed on post-operative day 3 and 5, if there
was no suspicion of leakage, i.e. amylase content in the drain
fluid not higher than three times the serum amylase level and
no bilirubin detected. Single-shot prophylactic antibiotics were
given before the incision.
Technical aspects of the operation did not vary during the
study period. Patients were discharged when the pain was con-
trolled by oral medication, the patient was autonomous
(ambulation, shower, eating and getting out of bed) and an
oral diet was well tolerated.
Score parameters
The time point for the age was the operation date. In our
study, tumour size was measured on pre-operative CT as
recommended by the original article by Hsu et al. Tumour
differentiation was based on post-operative pathology as a pre-
operative tumour biopsy was not routinely undertaken at our
institution. Poor differentiation was defined as G3 or G4
according to the American Joint Committee on Cancer.24 Of
note, in their article Hsu et al. also used the post-operative
pathology results and not the pre-operative biopsy to define
and validate the EMRS.18 Hypertension, diabetes mellitus,
cardiac disease or chronic obstructive pulmonary disease were
assessed pre-operatively.
Post-operative complications and resection margins
Post-operative complications were assessed according to the
Dindo–Clavien classification.25 Definitions of complications
were based according to a previous article from Johns
Hopkins.26 The definition of a clearance margin was based on
the 7th Edition of the TNM classification by the American Joint
Committee on Cancer (AJCC).27 Microscopically, a positive
resection margin (R1) was defined as the presence of tumour
cells at the resection margin (‘0 mm rule’).27–29 A R2 resection
was defined as a macroscopic positive margin and R0 as the
absence of microscopic tumour cells at the resection margin.27–29
Outcomes and statistical analysis
Survival time and EMRS were calculated for every single
patient. Based on these two results, relative risks (RR) of 9-
and 12-month mortality were calculated (EMRS of 0 was
defined as the reference, corresponding to a RR of 1). The
found RR were compared to the RR of the original EMRS
article. Comparisons were performed with Mann–Whitney U-
tests for non-Gaussian continuous variables and with Fisher’s
exact tests for discrete variables. Univariate analysis was per-
formed to identify parameters predicting early death 9 and
12 months after PD. Survival curves were calculated using the
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Kaplan–Meier technique. The overall median follow-up was cal-
culated by inverting the status indicators of the Kaplan–Meier
survival curve as described by Schemper and Smith.30 Compar-
isons of the survival curves were done by a log-rank (Mantel–
Cox) test. A P-value <0.05 was considered to be statistically
significant. The RR at which the P-value was <0.05 defined
our cut-off value for the EMRS. GraphPad Prism 5 for Mac
OS X (GraphPad Software Inc.) was used for calculation and
analysis.
The study was approved by the local Ethics Committee
(protocol number: 34/13).
Results
There were 270 patients who underwent a PD for various aeti-
ologies during the study period. PD for adenocarcinoma of the
pancreatic head was performed in 130 patients. Three patients
were excluded as a result of missing data and another seven
patients owing to early post-operative death (grade V complica-
tion), leaving 120 patients for analysis. The seven post-operative
deaths were due to haemorrhage (3x), multiple organ failure
(1x), a massive pulmonary embolism (1x), a gastric fistula (1x)
and colon ischaemia (1x). None of these seven deaths were
related to a tumour progression. Among the 10 excluded
patients, three patients had an EMRS of 1, three patients an
EMRS of 2, three patients an EMRS of 3 and one patient an
EMRS of 4. Calculations of the RR with these excluded patients
did not change the study findings (RR for EMRS of 4 = 5.7).
Table 1 resumes the patients’ characteristics, pre-operative
data, operative results and post-operative outcomes classified
regarding the 9- and 12-month mortality, respectively. No
patient received neoadjuvant treatment. Age >75 years, tumour
size ≥3 cm, low differentiation grade (G3, G4), the presence of
comorbidities (i.e. diabetes mellitus, hypertension, cardiovascu-
lar diseases, or chronic obstructive pulmonary disease), R1 or
R2 resection, and vascular or perineural invasion were associ-
ated with a significantly decreased survival <9 months after
PD. A tumour size ≥3 cm, low differentiation grade (G3, G4)
and R1 or R2 resection were statistically significant risk factors
for survival <12 months. The four EMRS parameters were thus
significant risk factors for 9-month mortality. Pre-operative
available statistically significant risk factors for early tumour-
related death (9-month mortality) were increased patient age,
tumour size ≥3 cm and comorbidities.
Thirty-three patients (28%) died during the first 9 months
after the operation and 45 patients (38%) during the first
post-operative year. Sixty-eight patients (57%) received post-
operative chemotherapy, whereby most of them (94%) received
gemcitabine, and the remaining patients received oxaliplatin or
FOLFIRI (leucovorin, fluorouracil and irinotecan). The R0
resection rate was 62% (74 patients), the R1 resection rate
33% (39 patients) and the R2 resection rate 5% (7 patients).
The predominant T stage was T3 in 92 patients (77%). The T1
stage was observed in three patients, T2 stage in 20 patients
and T4 stage in 5 patients. The median tumour size based on
pathology reports was 3 cm (interquartile range: 2.3–4 cm).
Overall complications appeared in 64% (77/120) of the
patients. Major complications (IIIa–IVb) appeared in 30%
Table 1 Risk factors for early mortality 9 (a) and 12 months (b)
after a pancreaticoduodenectomy (PD) for adenocarcinoma
(a)
Survival
≥ 9 months
N = 87
Survival
< 9 months
N = 33
P-value
Age >75 years 21 15 0.028
BMI >25 kg/m2 29 8 0.383
Women 42 15 0.840
Tumour size ≥ 3 cm 33 27 <0.001
Differentiation (G1/2/3) 16/51/20 2/18/13 0.029
Comorbidities 44 24 0.039
Postoperative CHT 51 17 0.539
Pylorus preservation 9 6 0.352
Portal vein resection 31 10 0.669
R0/R1/R2 59/25/3 15/14/4 0.047
Positive nodes 71 30 0.270
T stage (1/2/3/4) 3/16/65/3 0/4/27/2 0.522
Major post-operative
complications (III-IV)
25 11 0.659
Vascular invasiona 34 21 0.023
Perineural invasion 38 28 <0.001
(b)
Survival
≥ 12 months
N = 75
Survival
< 12 months
N = 45
P-value
Age > 75 years 21 18 0.227
BMI > 25 kg/m2 23 12 0.683
Women 37 20 0.706
Tumour size ≥ 3 cm 26 34 <0.001
Differentiation (G1/2/3) 15/45/15 4/23/18 0.036
Comorbidities 39 29 0.254
Post-operative CHT 44 24 0.575
Pylorus preservation 8 7 0.570
Portal vein resection 28 13 0.428
R0/R1/R2 53/20/2 21/19/5 0.017
Positive nodes 60 41 0.127
T stage (1/2/3/4) 3/14/56/2 0/6/36/3 0.325
Major postoperative
complications (III–IV)
22 14 0.839
Vascular invasiona 31 24 0.257
Perineural invasion 37 29 0.131
BMI, body mass index; CHT, chemotherapy.
aMicroscopic invasion of the small vessels.
Significant P-values appear in bold type.
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(36/120) of patients, and minor complications (I–II) appeared
in 34% (41/120) of patients. Patients with an EMRS of 0 or 1
had a complication rate of 69% vs. 61% for the patients with
an EMRS >1 (P = 0.438). Among patients with EMRS of 0 or
1 the most predictive factor of complications was the presence
of comorbidities (P = 0.001).
EMRS and mEMRS were calculated for every patient. Seven-
teen patients had an EMRS of 0, 27 patients an EMRS of 1, 45
patients an EMRS of 2, 25 patients an EMRS of 3, and 6
patients an EMRS of 4. For the modified version, 21 patients
had a mEMRS of 0, 32 patients a mEMRS of 1, 52 patients a
mEMRS of 2, and 15 patients a mEMRS of 3. RR of 9- and
12-month death after PD for the diverse scores are summa-
rized in Tables 2 and 3. A patient with an EMRS of 4 had 5.1
times and 4.5 times more risks of mortality at 9 and
12 months, respectively. In the original article, EMRS of 4 was
associated with a mortality RR of 10.7 at 9 months and 5.3 at
12 months. A patient with a mEMRS of 3 had 3.7 times and
3.2 times more risks of mortality at 9 and 12 months, respec-
tively. In the original article, mEMRS of ≥2 was associated with
a mortality RR of 2.5 at 9 months and 2.2 at 12 months.
The median follow-up time was 37 months (interquartile
range: 20–61 months). Kaplan–Meier survival curves are shown
in Figure 1. The overall median survival time according to
Kaplan–Meier analysis was 19 months (interquartile range
9–40).
The measures of the tumour size on pre-operative CT or
based on the pathology report were statistically significantly
different (median size on CT: 2.7 cm with interquartile range
2–3, median size on pathology reports: 3 cm with interquartile
range 2.3–4, P = 0.001).
Table 2 Early Mortality Risk Score (EMRS) associations with early
mortality 9 and 12 months after a pancreaticoduodenectomy (PD)
for adenocarcinoma
EMRS Mortality at 9 months Mortality at 12 months
Relative risk
(95% CI)
P-value Relative risk
(95% CI)
P-value
Score 0 Reference = 1 Reference = 1
Score 1 1.8 (0.4–8.0) 0.690 1.8 (0.6–5.8) 0.488
Score 2 2.5 (0.6–9.8) 0.200 2.0 (0.7–6.1) 0.225
Score 3 3.1 (0.8–12.5) 0.151 2.9 (1.0–8.8) 0.054
Score 4 5.1 (1.2–22.5) 0.048 4.5 (1.5–13.9) 0.020
CI, confidence interval.
Table 3 Modified Early Mortality Risk Score (mEMRS) associations
with early mortality 9 and 12 months after a
pancreaticoduodenectomy (PD) for adenocarcinoma
mEMRS Mortality at 9 months Mortality at 12 months
Relative risk
(95% CI)
P-value Relative risk
(95% CI)
P-value
Score 0 Reference = 1 Reference = 1
Score 1 1.8 (0.5–5.9) 0.493 2.0 (0.7–5.3) 0.223
Score 2 2.6 (0.8–7.7) 0.090 2.3 (0.9–5.9) 0.061
Score 3 3.7 (1.2–11.8) 0.025 3.2 (1.2–8.3) 0.017
CI, confidence interval.
Figure 1 Kaplan–Meier survival curves for Early Mortality Risk
Score (EMRS) and modified EMRS (mEMRS)23
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Discussion
In our cohort, an EMRS of 4 or a mEMRS of 3 were associated
with increased risks of early (9- and 12-month) tumour-related
post-operative mortality.
Even when surgery is performed early on for adenocarcinoma
of the pancreatic head, around one-third of patients will not sur-
vive the first post-operative year.10 Upfront surgery in high-risk
patients may not be appropriate, and alternative treatment
options may be worthwhile to be considered by avoiding the
post-operative morbidity. Simple pre-operative scores like the
EMRS could potentially be helpful tools to identify patients at
increased risk and to individualize treatment plans.
Risk factors of early death after PD identified by Hsu et al.
were age >75 years, tumour size ≥3 cm, poor differentiation,
the presence of comorbidities, no adjuvant chemotherapy,
node positivity, margin resection positivity, vascular invasion
(only for 12-month mortality) and post-operative complica-
tions.18 As some factors already are pre-operatively available,
they can be used for therapeutic decision-making. In our
study, age >75 years (only for 9-month mortality), tumour size
≥3 cm, low differentiation grade (G3, G4), the presence of
comorbidities (only for 9-month mortality), R1 or R2 resec-
tion, and vascular or perineural invasion (only for 9-month
mortality) were statistically significant risk factors for early
mortality after PD.
EMRS of 4 and modified EMRS of 3 were statistically signifi-
cant for higher RR of early death after PD for adenocarcinoma.
In contrast, long-term survivals based on Kaplan–Meier curves
were not different (Figure 1, P = 0.525 for EMRS and P = 0.343
for mEMRS). Of note, Hsu et al. did not calculate the difference
in long-term survival in the different scores. The fact that sur-
vival curves of the four EMRS are not different but that an
EMRS of 4 is a predictor of early mortality is remarkable, but it
might be related to the limited sample size of the study. The
overall median survival rate was 19 months, and 38% of the
patients were dead 12 months after the index operation. This
confirms the bad prognosis of pancreatic head adenocarcinomas
even when early operated. Moreover, occurrence of severe com-
plications among incomplete resections (R1) affects the long-
term survival and predicts a poor outcome.31
Age >75 years and the presence of comorbidities were pre-
dictors of survival <9 months but not of survival <12 months.
On the contrary, a tumour size ≥3 cm and low differentiation
grade were predictors of mortality for both 9 and 12 months.
The patient-related factors (i.e. age and comorbidities) reflect
the frailty of the patients. Fragile and weak patients are at high
risk of dying during the early post-operative period. This could
explain the difference in the predictive patient-related factors
between the early mortality at 9 months and 12 months (a
majority of polymorbid and old patients die before 9 months).
Measurements of the tumour size were based on the pre-
operative CT-scanner as recommended by the princeps article
by Hsu et al..18 The size of the tumours on CT and measured
in pathology were compared and showed a statistically signifi-
cant difference (P = 0.001). In our study, a pre-operative
CT scan underestimated the tumour size as found in other
studies.32,33
In our centre, patients diagnosed with adenocarcinoma of
the pancreas do not routinely undergo a tumour biopsy before
treatment, or only if neoadjuvant chemotherapy is potentially
considered. Therefore, tumour differentiation was assessed via
pathology reports. In institutions where a pre-operative biopsy
is not performed, the modified EMRS is a simple score that
can easily be used and calculated in clinical practice. Modified
EMRS probably represent a more useful generalizable tool than
the standard EMRS comprising the tumour differentiation.
In the article of Hsu et al., 53% of the operated patients
received adjuvant chemotherapy compared to 57% in our
group.18 There was a difference in terms of chemotherapy type,
which can play a role in the differences of the predictive values
of the EMRS between this study data and Hsu’s. In the EMRS
manuscript, 94% of patients with adjuvant chemotherapy
received 5-fluorouracil whereas 94% of our patients received
gemcitabine.
Complication rates were similar between a low-risk (EMRS
of 0 or 1) and a high-risk of mortality (EMRS >1) patients
(P = 0.438). This result shows that complications can occur
independently of the disease or the patient. EMRS thus repre-
sents a good predictor of early mortality but not a good pre-
dictor of post-operative complications.
Our study has several limitations that must be acknowl-
edged. First of all, as the scores were calculated in a retrospec-
tive way, all possible confounding factors were sometimes not
available in the charts. Moreover, 120 patients to validate this
score may lack statistical power (in particular for the RR <4).
Included patients received either adjuvant chemotherapy or no
post-operative treatment. These parameters were not taken into
account for the validation process.
Clinical implications of the score still need to be evaluated.
Patients with a high EMRS could maybe benefit from neoadju-
vant treatment. Moreover, it could be suggested that reduction
of malnutrition, smoking cessation, or other interventions to
minimize post-operative morbidity would be of interest in high
EMRS, but this is not clearly established as these interventions
would probably improve the immediate post-operative mor-
bidity and mortality. Finally, post-operative management
should be particularly careful in such high-risk patients.
EMRS represents a predictive score of early mortality after
PD, but does not correlate with long-term survival. This study
shows that the EMRS and the modified EMRS were predictive
of short-term mortality in a different patient cohort. EMRS
and mEMRS can, therefore, be used in clinical daily practice.
Prospective studies to verify our findings and algorithm
development based on this score are required to enhance the
usefulness of this simple predictive score.
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